Asia Tech Wire (Jan 24) -- Chinese pharmaceutical company WuXi XDC (2268.HK) has partnered with South Korean peer Celltrion Inc. (068270.KS) on the research, development and manufacturing of antibody-drug conjugates.

WuXi XDC and Celltrion said on Tuesday that they have signed a Memorandum of Understanding (MOU) for comprehensive and integrated services which refer to the development, and manufacturing of bioconjugates include antibody-drug conjugates(ADCs).

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP manufacturing, within the global territory.

And WuXi XDC will be strategic service partner to support Celltrion's innovative pipeline advances, providing comprehensive services from process development to one-stop GMP manufacturing, aiming to accelerate the development of ADCs at a fast speed and with high quality.

Celltrion is a biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing and manufacturing innovative therapeutics that improve people's lives worldwide.

WuXi XDC, spun off from Chinese pharmaceutical giant WuXi Biologics (Cayman) Inc. (2269.HK) in 2023 and listed on the Hong Kong stock exchange, is a global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market.